At Minuendo we are passionate about sound and the sense of hearing. We are equally concerned about the state of hearing for both consumers as well as professionals, ranging from musicians to workers in the construction industry. Minuendo was founded in 2018 by a team with extensive experience in acoustics, hearing protection, and product development. Our mission is to deliver category-defining hearing protection products that users will truly enjoy wearing and that will provide real protection.  Shortly after starting the company, we raised a total of EUR 2.5 million from investors such as Construct Venture and EU grants to accelerate our development. Minuendo is a fast-growing start-up based in Oslo. The founders have a track record of start-ups and product development. We have raised NOK 25 million since we started the company in the fall of 2018. We have offices in the loft at Pakkhuset close to Stortinget.  We are just about to launch our first product internationally and we need your help to make sure we succeed with product marketing and reaching users online that we otherwise would not have sold to through traditional channels. What we have made is a new high-end prosumer earplug that reduces noise and protects your hearing, while maintaining high fidelity of ambient sounds, such as music from your own instrument or at concerts. The technology and product are unique, and so must our digital marketing.

Tubeify.tv is the world’s first video site to aggregate videos in a smart and automated way from social media platforms, to provide a full-service website with popular and trending videos, social feeds and merchandise from our video partners. Tubeify.tv does not store any videos in its platform but uses different technologies and business models to partner, source and ingest the most popular videos. Automatic data collection, smart tagging and user behavior tracking provide for enhanced customer experiences and builds engagement Tubeify’s hallmarks include: 1) A well targeted user experience for the Gen ZY audience , with a smart use of data and editors’ curation to show cool and trending videos. 2) An Eshop for creators, influencers and partners’ channel merchandise 3) A branded channel page for video partners’ social media activities Tubeify is Headquartered in Norway, with a skilled management team located in the Nordics, UK, USA and Canada.

We believe that live esports should be available to everyone, in a way that makes it easy to follow and easy to understand. Our goal is to make it available anytime, anywhere, and to unify it all in one place. That’s why we’re building a platform that will revolutionize the way you consume live esports.

Hundreds of thousands of movies and television series are released every year to the joy of local audiences, but to the annoyance of global audiences who have to wait a long time before these are available in their country. This is because distributors need to take them through an intensive and complex compliance check for every market before they distribute. Our company, Visualyst, is helping publishers get more movies and series cleared for distribution to consumers faster using artificial intelligence and machine learning.

Klarna offer smoooth payments to 130.000 webshops and retailers across the globe. The company has 2500 employees spread over our 14 markets. Klarna Checkout is the main product, which offers merchants 1 integration, 1 agreement, 1 settlement for handling payments online and in stores. Klarna Norway AS has 15 (and increasing) employees who work at the 26th floor at Posthuset in Oslo.

UpNorth Ventures was formed in 2017 by a team of experienced entrepreneurs/executives with broad business, financial, tech and entrepreneurial backgrounds. The team is supported by a network of tech resources and other. We are growing, and currently looking for new partners and employees. We believe in building companies from scratch with a bootstrap mentality that makes them profitable early on. Are you an entrepreneur, investor or just curious, then let us know at hello@upnorth.vc

24Nettbutikk is one of the leading e-commerce platforms in the Norwegian market. More than 1200 small and medium businesses currently use the platform to sell their products through digital channels. 24Nettbutikk focuses on developing strong partnerships and technical integrations with leading providers of services such as logistics, payments and marketing to offer a complete solution for our merchants at a competitive cost. We have a strong focus on our customer's success and work hard every day to ensure that customers experience a short time to value and continuous growth in sales volume.

OptoScale supplies fish farmers with precise and relevant data empowering them to make decision that improve productivity, sustainability, and animal welfare. Our data informs fish farmers about how their production is going, by accurately measuring the size of fish, growth, welfare status, and parasite counting. Our head office is in Trondheim, Norway, and we deliver to our great customers around the world. We are continuously interested in hiring great people across most of our functions: HW development, AI/ML, electronics, sales and customer success.

Entro is an energy- and environmental consultancy firm with two clients – our customers and the environment. We save our customers time and money, and we help the environment by reducing energy consumption and carbon footprints. Entro has about 60 employees in Oslo, Trondheim, and Bergen. We had a turnover of NOK 63 million in 2016 and saved our customers NOK 400 million. Entro has a unique interdisciplinary expertise with a good mix of practical and academic skills. Among our staff we have more trade certificates in electrical and construction, more than 60% of the employees are civil engineers and engineers and we have several employees with training in economics and management. We have expertise in electrical, plumbing, building, environment, and IT.

Oncoinvent AS is a privately held Norwegian company established in 2010. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The innovations being developed by Oncoinvent AS are a result of the extensive experience with the development of radionuclide-based cancer treatments of two of the founders, Dr. Roy H. Larsen and Professor of clinical oncology Øyvind S. Bruland. Larsen and Bruland are the inventors of the first FDA and EMA-approved alpha-emitting pharmaceutical product Xofigo® (Bayer AG), as well as of the beta-emitting radio-immunotherapeutic product candidate Betalutin® (Nordic Nanovector ASA). Oncoinvent's lead product candidate, Radspherin®, is a novel alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in body cavities. Radspherin® has been shown to cause a significant reduction in tumor cell growth. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be the treatment of peritoneal carcinomatosis. Clinical development will be conducted in collaboration with European and American clinical research centers.

Biozep is discovering and developing first-in-class drug products for the treatment of severe eye diseases which can lead to vision loss and where it is a high unmet medical need. Biozep has discovered novel drug substances based on bioactive lipids which modulate central pathways involved in the pathogenesis of eye diseases. Targets and biomarkers are identified based on a system biology approach combined with in-depth knowledge about bioactive lipids, their endogenous synthesis and mechanisms of action. Biozep has made a prototype drug product based on our lead compound for topical administration and the product will be tested in animal models in 2018. Our goal is to start clinical studies in 2020. Biozep is a company depending on both internal and external resources. Biozep has established its own laboratory in Oslo in order to do synthesis, purification, quality control and chemical development in-house. The biological testing of the drug substances is performed in collaboration with carefully selected contract research organizations both in Europe and the USA. In order to reach the market as fast as possible and to reduce risk, Biozep will seek strategic partnerships early in the drug development phase. Biozep seeks partners with complementary competence and with resources to conduct clinical trials and with market access. We are already in dialogue with potential partners and hope to sign an agreement in 2018-19.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Hvem er vi ? TICOM har en liten, men sammensveiset kjerne med bakgrunn innenfor innovativ mobilteknologi, og som de senere årene har jobbet med å utvikle lignende høykvalitetsprodukter innenfor klokker og headsets. Det er også gjennom denne kunnskapen og erfaringen våre medlemmer har opparbeidet seg et unikt kontaktnettverk I Asia, noe som igjen gjør at TICOM har tilgang til kvalitetsprodukter til priser få kan konkurrere med I vesten. Hvis noen I det hele tatt. Vi har egne og lokale representanter “på bakken” I Kina og Thailand. Samtidig har vi tilknyttet vårt nettverk en ny ressurs innen PR, Medier og samfunnskontakt som har lang internasjonal erfaring på høyt plan, blant annet I FN hvor han begynte I WHO I 1993.

Hei, mitt navn er Erik Johannesen og er gründer i det norske selskapet ID TAG TECHNOLOGY GROUP AS. Selskapet ID TAG TECHNOLOGY har en idé og teknologi som vi anser som støttende til innsamling av BIG DATA, og et utall andre muligheter innenfor dette konseptet. Vår ambisjon er at ID TAG TECHNOLOGY skal kan skape et nytt verdensomspennende markedsføringskonsept. ID TAG TECHNOLOGY sin patenterte teknologi/konsept har til hensikt å være en «plattform» for mange industrielle behov. Vi anser at vi kan lisensiere ut vår teknologi til logistikk, broadcast, marine, olje og gass mm. Utallige muligheter. Tenk deg at du tar et bilde med mobilkamera og kan se hvem som er på bildet med informasjon om vedkommende, samt at du kan se hvilken merkevare-/produsent som har produktene på bildet, i sanntid. Deretter trykker du på produktet på bildet som inneholder en url, og du blir sendt videre til produktets nettsted. Dette er ikke gjenkjennelses teknologi eller maskin learning, men rett informasjon som er skapt av de som ønsker å informere kundene i den store verden. ID TAG TECHNOLOGY ble etablert 2011, har en positiv PCT-rapport, og innleverte patentsøknader februar 2015 på en teknologi/konsept for å plassere/identifisere elektroniske tags/sensorer innenfor en billedramme i sanntid, både stillbilder og video/film i en rekke land. Både ideen og teknologien har oppfinnerhøyde. Teknologien som er beskrevet i patentsøknadene er utviklet/forsket på i samarbeid med SINTEF, og har pågått siden begynnelsen av 2011. Vi har nå utviklet en lab modell for å bevise at dette lar seg gjennomføre – dette kan du få se. ID TAG TECHNOLOGY GROUP har blitt innvilget patent i Norge, USA og Kina (2017). Det er for øvrig søkt patent i EPO, Russland, Hong Kong, Japan og Sør Korea. Søknadsprosessen går over all forventning. Teknologien kan benyttes både i profesjonelt utstyr og i personlige enheter som smarttelefoner og nettbrett/PC og egenutviklede hardwareprodukter for industrielle behov. Bruksområdene er mange, og vi har spesielt sett på kringkasting/film (produktplassering), markedsføring/varehandel, transport/distribusjon og sosiale medier. Vi ser store muligheter innenfor markedsføring og salg hvor interessenten har mer kontroll enn det som dagens trender tilsier.   Se gjerne våre illustrerende konsept filmer på vår hjemmeside: http://www.idtagtech.com  Med vennlig hilsen  Erik Johannesen Mob: +47 918 71 610 E-mail: erik.johannesen@bbnett.no Hjemmeside: http://www.idtagtech.com

Innovation Dock is a living, energetic innovation hub for entrepreneurs, innovators, and growth companies in Stavanger, Norway. Four buildings of prime office space, co-working, and conference facilities with a front-row view of the fjords and mountains, located in the most energetic part of Stavanger city center; the growing Stavanger east.